ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1714

Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1500

Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1612

Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1602

Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City

Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

8:30AM-10:30AM: Abstract Number: 1723

Factors Associated with Postpartum Flare in Women with Lupus

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1849

False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1678

Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

8:30AM-10:30AM: Abstract Number: 1771

First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1550

Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1494

Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1838

Further Construct Validation of the

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1799

Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1551

Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1581

Genetic Effects on the Transition from Hyperuricemia to Gout

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

SLE – Treatment Poster (1732–1772)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].